FDA approves Vyvgart label expansion for generalized myasthenia gravis
Updated
Updated · MarketWatch · May 8
FDA approves Vyvgart label expansion for generalized myasthenia gravis
13 articles · Updated · MarketWatch · May 8
Argenx said the expanded indication covers all serotypes of adult patients and includes Vyvgart Hytrulo as well as Vyvgart.
The supplemental Biologics License Application was backed by Phase 3 data showing rapid and sustained symptom improvement in patients with the rare chronic autoimmune disease.
Generalized myasthenia gravis can cause debilitating and life-threatening muscle weakness, making the decision a broader treatment access expansion for eligible adults.
Vyvgart's approval now covers all gMG patients, but will its high cost make this breakthrough treatment truly accessible for everyone?
As competitors launch new gMG drugs, can Vyvgart's broader approval defend its market dominance and billion-dollar sales forecast?
Does the FDA's faster approval path for rare diseases signal a major shift in how all future drugs will be evaluated?